FDA Approves First Drug Shown to Help Patients with Infantile Onset Niemann-Pick Disease Type C Live Longer

The FDA has approved Lembaz (adrabetadex), the first treatment shown to reduce the risk of death in patients with infantile onset Niemann-Pick disease type C (NPC), a rare inherited disease that causes progressive neurological decline.

Lembaz received Breakthrough Therapy designation. The FDA granted approval of Lembaz to Mandos, LLC, a subsidiary of Beren Therapeutics, PBC.